MCID: LRY017
MIFTS: 44

Laryngeal Disease

Categories: Oral diseases, Respiratory diseases

Aliases & Classifications for Laryngeal Disease

MalaCards integrated aliases for Laryngeal Disease:

Name: Laryngeal Disease 12 15 37 17
Laryngeal Diseases 44 70
Laryngeal Anomalies 6

Classifications:



External Ids:

Disease Ontology 12 DOID:786
ICD9CM 34 478.70
MeSH 44 D007818
NCIt 50 C26810
SNOMED-CT 67 195863001
ICD10 32 S12.8
UMLS 70 C0023051

Summaries for Laryngeal Disease

MalaCards based summary : Laryngeal Disease, also known as laryngeal diseases, is related to larynx cancer and hirschsprung disease with heart defects, laryngeal anomalies, and preaxial polydactyly, and has symptoms including dyspnea and stridor. An important gene associated with Laryngeal Disease is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include trachea, skin and endothelial.

Wikipedia : 73 The larynx (/ˈlærɪŋks/), commonly called the voice box, is an organ in the top of the neck involved in... more...

Related Diseases for Laryngeal Disease

Diseases related to Laryngeal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 larynx cancer 29.2 MIRLET7A1 MIR744 MIR486-1 MIR34C MIR34A MIR31
2 hirschsprung disease with heart defects, laryngeal anomalies, and preaxial polydactyly 11.2
3 laryngitis 11.0
4 laryngomalacia 10.9
5 acquired laryngomalacia 10.9
6 esophagus adenocarcinoma 10.4 MIR21 MIR196A1 MIR143
7 pleural cancer 10.4 MIRLET7A1 MIR17 MIR139
8 miyoshi muscular dystrophy 1 10.4 MIR34A MIR21 MIR155 MIR148A
9 lower lip cancer 10.4 MIR31 MIR21
10 polymyositis 10.4 MIR34A MIR21 MIR155
11 inclusion body myositis 10.4 MIR34A MIR21 MIR155
12 pre-malignant neoplasm 10.4 MIR17 MIR143 MIR139
13 feingold syndrome 1 10.4 MIR20A MIR17 MIR106B
14 dermatomyositis 10.4 MIR34A MIR21 MIR155 MIR148A
15 in situ carcinoma 10.4 MIR17 MIR143 MIR139
16 leiomyoma, uterine 10.4 MIR486-1 MIR34A MIR21 MIR139
17 acute myocardial infarction 10.4 MIR486-1 MIR34A MIR21 CA3
18 heart valve disease 10.4 MIR486-1 MIR21 MIR17
19 pleural disease 10.4 MIRLET7A1 MIR17 MIR125A
20 retinal vascular disease 10.4 MIR21 MIR20A MIR17
21 bone sarcoma 10.4 MIR9-1 MIR21 MIR17 MIR139
22 intrinsic cardiomyopathy 10.3 MIR486-1 MIR296 MIR21
23 bronchial disease 10.3 MIR21 MIR17 MIR155
24 ovarian serous carcinoma 10.3 MIR21 MIR20A MIR143 MIR125A
25 laryngeal squamous cell carcinoma 10.3 MIR744 MIR34A MIR21 MIR155 MIR148A
26 chromosomal duplication syndrome 10.3 MIR9-1 MIR486-1 MIR196A1 MIR155
27 primary bacterial infectious disease 10.3 MIR21 MIR155 MIR125A
28 nemaline myopathy 10.3 MIR34A MIR155 MIR148A
29 aortic valve disease 2 10.3 MIR486-1 MIR34A MIR21 MIR17 MIR106B
30 thyroid gland disease 10.3 MIR9-1 MIR17 MIR125A
31 bile duct cancer 10.3 MIR9-1 MIR31 MIR21 MIR17
32 muscular dystrophy, duchenne type 10.3 MIR486-1 MIR34A MIR21 MIR155 MIR148A
33 chromosomal deletion syndrome 10.3 MIR9-1 MIR31 MIR17
34 leukocyte disease 10.3 MIR21 MIR196A1 MIR17 MIR155 MIR125A
35 kidney cancer 10.3 MIR21 MIR20A MIR17 MIR106B
36 gallbladder disease 10.3 MIR196A1 MIR17 MIR143
37 melanoma, uveal 10.3 MIR9-1 MIR149 MIR143 MIR125A
38 renal fibrosis 10.3 MIR21 MIR196A1 MIR155
39 b-cell lymphoma 10.3 MIR34A MIR21 MIR20A MIR17 MIR155
40 pancreatic ductal adenocarcinoma 10.3 MIR31 MIR21 MIR196A1 MIR155 MIR148A MIR143
41 non-alcoholic fatty liver disease 10.3 MIR34A MIR31 MIR21 MIR17 MIR155
42 autoimmune disease of central nervous system 10.3 MIR9-1 MIR155 MIR125A
43 ocular cancer 10.3 MIR9-1 MIR196A1 MIR17 MIR143 MIR125A
44 tongue disease 10.3 MIR486-1 MIR31 MIR21 MIR196A1 MIR17 MIR139
45 retinal cancer 10.3 MIR9-1 MIR486-1 MIR196A1 MIR17 MIR125A
46 digeorge syndrome 10.3 MIR9-1 MIR31 MIR196A1 MIR17
47 lymphoma, hodgkin, classic 10.3 MIR21 MIR20A MIR155
48 autoimmune disease of the nervous system 10.3 MIR9-1 MIR155 MIR125A
49 infratentorial cancer 10.3 MIR9-1 MIR34C MIR20A MIR196A1 MIR17
50 intestinal benign neoplasm 10.3 MIR21 MIR20A MIR196A1 MIR17 MIR143 MIR139

Graphical network of the top 20 diseases related to Laryngeal Disease:



Diseases related to Laryngeal Disease

Symptoms & Phenotypes for Laryngeal Disease

UMLS symptoms related to Laryngeal Disease:


dyspnea; stridor

Drugs & Therapeutics for Laryngeal Disease

Drugs for Laryngeal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Amitriptyline Approved Phase 2, Phase 3 50-48-6 2160
7
Perphenazine Approved Phase 2, Phase 3 58-39-9 4748
8
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
10 Nicotinic Acids Phase 3
11 Vitamin B3 Phase 3
12 Antimitotic Agents Phase 3
13 Tubulin Modulators Phase 3
14 Antimetabolites Phase 3
15 Vitamin B9 Phase 3
16 Vasodilator Agents Phase 3
17 Vitamin B Complex Phase 3
18 Vitamins Phase 3
19 Folate Phase 3
20 Lipid Regulating Agents Phase 3
21 Hypolipidemic Agents Phase 3
22 Antidepressive Agents Phase 2, Phase 3
23 Psychotropic Drugs Phase 2, Phase 3
24 Analgesics, Non-Narcotic Phase 2, Phase 3
25 Neurotransmitter Agents Phase 2, Phase 3
26 Amitriptyline, perphenazine drug combination Phase 2, Phase 3
27 Analgesics Phase 2, Phase 3
28 Adrenergic Agents Phase 2, Phase 3
29 Antipsychotic Agents Phase 2, Phase 3
30 Antidepressive Agents, Tricyclic Phase 2, Phase 3
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
33
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
34
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
37 Raspberry Approved Phase 1, Phase 2
38
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
39
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
40
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
41
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
42
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
44
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
45
Aprepitant Approved, Investigational Phase 2 170729-80-3 151165 6918365
46
Fosaprepitant Approved Phase 2 172673-20-0 219090
47
Palonosetron Approved, Investigational Phase 2 119904-90-4, 135729-56-5 148211
48
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
49 Kava Approved, Investigational, Nutraceutical Phase 2 9000-38-8
50
Nimorazole Investigational Phase 1, Phase 2 6506-37-2

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Role of Esophageal and Laryngeal Biopsies in Suspected Laryngopharyngeal Reflux Completed NCT00373997 Phase 4
2 Do Laryngeal Biopsy Findings Predict Treatment Response in Suspected Laryngopharyngeal Reflux Completed NCT00444145 Phase 4 Prevacid
3 An Interdisciplinary Interpretation of Transnasal Esophagoscopy Findings Completed NCT00372918 Phase 4
4 A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma. Completed NCT00147732 Phase 3
5 Randomized Placebo-Controlled Trial of BID Lansoprazole in Isolated Chronic Post Nasal Drip Completed NCT00335283 Phase 3 Lansoprazole Tablet;lansoprazole;placebo
6 PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS Completed NCT00002839 Phase 3 cisplatin;fluorouracil
7 Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
8 Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline Recruiting NCT02552225 Phase 2, Phase 3 Amitriptyline
9 Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitryptiline Terminated NCT02434523 Phase 2, Phase 3 Amitriptyline
10 Effect of Aggressive Acid Suppression With Esomeprazole on Vocal Cord Granulomas: Randomized Placebo-Controlled Trial Withdrawn NCT00567658 Phase 3 Esomeprazole
11 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
12 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
13 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
14 A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors Completed NCT00063895 Phase 1, Phase 2 erlotinib hydrochloride
15 Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx Completed NCT00508664 Phase 2 Cetuximab;Docetaxel;Cisplatin (TP);5-Fluorouracil (TPF) (only until Feb 2009)
16 Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00410826 Phase 2 erlotinib hydrochloride;cisplatin
17 Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma Completed NCT00387335 Phase 2 sunitinib malate
18 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
19 A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck Completed NCT00055913 Phase 1, Phase 2 erlotinib hydrochloride
20 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
21 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
22 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
23 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
24 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
25 A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Completed NCT00098631 Phase 2 lapatinib ditosylate
26 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
27 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
28 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
29 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
30 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
31 A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx Completed NCT02055989 Phase 1, Phase 2
32 Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity Completed NCT01733823 Phase 1, Phase 2
33 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
34 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
35 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
36 Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) Recruiting NCT02757222 Phase 1, Phase 2
37 Left, Right, or Bilateral Thalamic Deep Brain Stimulation for Voice Tremor: A Prospective, Randomized, Double-Blinded Trial Recruiting NCT02960243 Phase 1, Phase 2
38 Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck Active, not recruiting NCT01884259 Phase 2 Docetaxel;Cisplatin;5-fluorouracil
39 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
40 A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Terminated NCT01192815 Phase 2 erlotinib hydrochloride
41 A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head & Neck Cancer Undergoing Concurrent Chemotherapy and Radiation Terminated NCT00895245 Phase 2 fosaprepitant dimeglumine;cisplatin;palonosetron hydrochloride;dexamethasone
42 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck Terminated NCT01682031 Phase 2 cisplatin
43 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
44 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
45 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
46 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
47 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
48 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
49 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
50 A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel

Search NIH Clinical Center for Laryngeal Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Laryngeal Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Laryngeal Disease:
Laviv azficel-T, dermal fibroblasts for scarring
Embryonic/Adult Cultured Cells Related to Laryngeal Disease:
Skin-derived fibroblasts PMIDs: 21287562 10805306 23211390

Cochrane evidence based reviews: laryngeal diseases

Genetic Tests for Laryngeal Disease

Anatomical Context for Laryngeal Disease

MalaCards organs/tissues related to Laryngeal Disease:

40
Trachea, Skin, Endothelial, Thyroid, Liver, Cortex, Salivary Gland

Publications for Laryngeal Disease

Articles related to Laryngeal Disease:

(show top 50) (show all 466)
# Title Authors PMID Year
1
Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab. 61
33811681 2021
2
Laryngeal Pemphigoid Evolution and Response to Treatment. 61
33583674 2021
3
The Use of 532-Nanometer-Pulsed Potassium-Titanyl-Phosphate (KTP) Laser in Laryngology: A Systematic Review of Current Indications, Safety, and Voice Outcomes. 61
31928082 2021
4
[Study on the measurement of glottic proportion in subjects with normal larynx]. 61
33540998 2021
5
A Review of Pharmacological and Toxicological Effects of Sophora tonkinensis with Bioinformatics Prediction. 61
33622209 2021
6
Quantitative evaluation of the human vocal fold extracellular matrix using multiphoton microscopy and optical coherence tomography. 61
33510352 2021
7
KTP Laser Treatment of Early Glottic Cancer: A Multi-Institutional Retrospective Study. 61
32627613 2021
8
Involvement of Laryngopharyngeal Reflux in Select Nonfunctional Laryngeal Diseases: A Systematic Review. 61
32571152 2021
9
Factors Related to Extralaryngeal Spread in Juvenile Recurrent Respiratory Papillomatosis. 61
33274778 2020
10
Method for Vertical Calibration of Laser-Projection Transnasal Fiberoptic High-Speed Videoendoscopy. 61
31151853 2020
11
Study of spatiotemporal liquid dynamics in a vibrating vocal fold by using a self-oscillating poroelastic model. 61
33138511 2020
12
[Analysis of the association between helicobacter pylori infection and laryngeal lesions]. 61
33254299 2020
13
Mycosis Fungoides of the True Vocal Folds: A Case Report. 61
32340473 2020
14
Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery. 61
33088690 2020
15
Infiltrative laryngeal disease in dogs. 61
32715485 2020
16
Laryngopharyngeal Reflux in Hypertrophic Laryngeal Diseases. 61
32865459 2020
17
Intrinsic Laryngeal Lipoma Treated with Transoral CO₂ Laser Microsurgery: An Unusual Case Report. 61
32619210 2020
18
Photodynamic therapy for the treatment of tracheobronchial papillomatosis: A multicenter experience. 61
32145373 2020
19
Role of Video Laryngostroboscopy in Benign Disease of Larynx. 61
32551287 2020
20
Development and Validation of the Thyroidectomy-Related Voice and Symptom Questionnaire (TVSQ). 61
32451255 2020
21
Infection Rates After Microlaryngeal and Open Phonosurgery: The Role of Postoperative Antibiotics. 61
31424561 2020
22
Upper Airway Obstruction Due to Primary Laryngeal Blastomycosis in a Dog. 61
32182114 2020
23
Laryngeal Disease in Dogs and Cats: An Update. 61
31882166 2020
24
Use of Latissimus Dorsi Myocutaneous Island Flap for Pharyngeal Reconstruction in Setting of Postoperative Wound Infection in Salvage Laryngectomy. 61
32205969 2020
25
The future of robotic surgery in otolaryngology - head and neck surgery. 61
31841882 2020
26
Multi-Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis. 61
30963598 2020
27
Laryngeal Candidiasis Mimicking Supraglottic Carcinoma by Prolonged Inhaled Steroid Therapy: A Case Report and Review of the Literature. 61
32107940 2020
28
Dietary factors associated with inflammatory laryngeal disease in South Korea. 61
33382750 2020
29
Paroxysmal Laryngospasm: A Rare Condition That Respiratory Physicians Must Distinguish from Other Diseases with a Chief Complaint of Dyspnea. 61
32695244 2020
30
One lung ventilation management in a patient with Reinke's edema. 61
32480341 2020
31
[Innovative endoscopic technologies in the diagnosis of laryngeal diseases in adults and children]. 61
33474916 2020
32
Primary Immunoglobulin G4-Related Laryngeal Disease: A Case Series and Review of Literature. 61
33192112 2020
33
Original Research: Aerosolized Lidocaine: Effective for Safer Arousal After Suspension Laryngoscopy. 61
30227980 2020
34
Characteristics of Functional Dysphonia in Children. 61
30172669 2020
35
Laryngeal amyloidosis. 61
31651423 2019
36
Direct Visualization of Laryngeal Mucociliary Clearance in Adults. 61
31271035 2019
37
Exploring stimulation patterns for electrical stimulation of the larynx using surface electrodes. 61
31414223 2019
38
Protective effect of aerobic exercise on the vocal folds against cigarette smoke exposure. 61
30980189 2019
39
Discrimination of "hot potato voice" caused by upper airway obstruction utilizing a support vector machine. 61
30485441 2019
40
Clinical and radiographic findings in cats with aspiration pneumonia: retrospective evaluation of 28 cases. 61
30843218 2019
41
Magnetic resonance imaging of the larynx in the pediatric population: A systematic review. 61
30680950 2019
42
Laryngeal metastases from breast cancer: A rare clinical entity. 61
30119910 2019
43
Diagnostic Accuracy of Dysphonia Classification of DSI and AVQI. 61
30203473 2019
44
Anatomy and Pathology of the Texel Sheep Larynx. 61
30818827 2019
45
HPV infection and clinical profiles in laryngeal diseases. A preliminary study. 61
31814599 2019
46
[Surgical treatment of laryngeal cysts in children with argonplasma coagulation]. 61
32027321 2019
47
Visible Vessels of Vocal Folds: Can they have a Diagnostic Role? 61
32008546 2019
48
Laryngeal reconstruction in children with recurrent respiratory papillomatosis. 61
30368371 2018
49
Proposal of a form for the collection of videolaryngostroboscopy basic findings. 61
29789936 2018
50
Detecting Laryngopharyngeal Reflux by Immunohistochemistry of Pepsin in the Biopsies of Vocal Fold Leukoplakia. 61
28756936 2018

Variations for Laryngeal Disease

Expression for Laryngeal Disease

Search GEO for disease gene expression data for Laryngeal Disease.

Pathways for Laryngeal Disease

GO Terms for Laryngeal Disease

Cellular components related to Laryngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 MIRLET7A1 MIR744 MIR486-1 MIR31 MIR21 MIR20A
2 extracellular exosome GO:0070062 9.76 MIRLET7A1 MIR9-1 MIR34A MIR21 MIR17 MIR155
3 extracellular vesicle GO:1903561 9.23 MIRLET7A1 MIR34A MIR21 MIR20A MIR17 MIR148A

Biological processes related to Laryngeal Disease according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.93 MIRLET7A1 MIR9-1 MIR744 MIR486-1 MIR34C MIR34A
2 positive regulation of angiogenesis GO:0045766 9.9 MIR143 MIR20A MIR21 MIR31
3 negative regulation of cell migration GO:0030336 9.89 MIR149 MIR21 MIR34A MIR9-1
4 negative regulation of inflammatory response GO:0050728 9.88 MIR149 MIR155 MIR20A MIR31
5 cellular response to hypoxia GO:0071456 9.87 MIR106B MIR155 MIR17 MIR34A
6 cholesterol homeostasis GO:0042632 9.83 MIR34A MIR155 MIR148A
7 negative regulation of angiogenesis GO:0016525 9.83 MIR106B MIR125A MIR143 MIR21 MIR34A
8 negative regulation of interleukin-6 production GO:0032715 9.82 MIR155 MIR149 MIR125A
9 negative regulation of gene expression GO:0010629 9.8 MIR106B MIR125A MIR155 MIR17 MIR20A MIR21
10 negative regulation of protein kinase B signaling GO:0051898 9.79 MIR20A MIR34A MIR34C
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.78 MIR17 MIR20A MIR21
12 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.78 MIR149 MIR155 MIR196A1 MIR20A
13 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.76 MIR106B MIR20A MIR21
14 negative regulation of stress fiber assembly GO:0051497 9.73 MIR149 MIR20A MIR21
15 positive regulation of sprouting angiogenesis GO:1903672 9.72 MIR125A MIR155 MIR31
16 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.71 MIR143 MIR20A MIR21
17 negative regulation of sprouting angiogenesis GO:1903671 9.71 MIR17 MIR20A MIR34A MIR34C
18 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.7 MIR17 MIR20A MIR31
19 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.69 MIR148A MIR155 MIR17
20 positive regulation of cardiac muscle hypertrophy GO:0010613 9.68 MIR21 MIR155
21 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.68 MIR34A MIR21
22 negative regulation of innate immune response GO:0045824 9.67 MIR21 MIR155
23 negative regulation of JAK-STAT cascade GO:0046426 9.67 MIR9-1 MIR155
24 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.67 MIR34A MIR17
25 positive regulation of connective tissue replacement GO:1905205 9.67 MIR155 MIR34A MIR34C
26 negative regulation of vascular endothelial growth factor production GO:1904046 9.67 MIR125A MIR17 MIR20A MIR34A
27 negative regulation of cell adhesion molecule production GO:0060354 9.66 MIR20A MIR155
28 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.65 MIR17 MIR155
29 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.65 MIRLET7A1 MIR125A
30 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR21 MIR125A
31 positive regulation of metalloendopeptidase activity GO:1904685 9.64 MIR21 MIR17
32 negative regulation of vascular wound healing GO:0061044 9.63 MIR34A MIR155
33 negative regulation of regulatory T cell differentiation GO:0045590 9.63 MIR155 MIR21
34 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.63 MIR125A MIR155 MIR31
35 negative regulation of STAT cascade GO:1904893 9.62 MIR125A MIR149
36 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.61 MIR17 MIR21
37 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.5 MIR143 MIR17 MIR20A
38 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.46 MIR155 MIR17 MIR20A MIR34C
39 miRNA mediated inhibition of translation GO:0035278 9.28 MIR106B MIR148A MIR155 MIR17 MIR20A MIR21

Molecular functions related to Laryngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 MIR9-1 MIR34A MIR31 MIR21 MIR20A MIR17
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.53 MIRLET7A1 MIR9-1 MIR34A MIR31 MIR296 MIR21
3 RNA polymerase II complex binding GO:0000993 9.33 MIR20A MIR139 MIR125A

Sources for Laryngeal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....